{"pmid":32453688,"title":"COVID-19, thromboembolic risk and thromboprophylaxis: learning lessons from the bedside, awaiting evidence.","text":["COVID-19, thromboembolic risk and thromboprophylaxis: learning lessons from the bedside, awaiting evidence.","Blood Transfus","Coppola, Antonio","Lombardi, Maria","Tassoni, Maria I","Carolla, Gaetano","Tala, Maurizio","Morandini, Rossella","Paoletti, Oriana","Testa, Sophie","32453688"],"journal":"Blood Transfus","authors":["Coppola, Antonio","Lombardi, Maria","Tassoni, Maria I","Carolla, Gaetano","Tala, Maurizio","Morandini, Rossella","Paoletti, Oriana","Testa, Sophie"],"date":"2020-05-27T11:00:00Z","year":2020,"_id":"32453688","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.2450/2020.0113-20","locations":["thromboprophylaxis"],"topics":["Treatment"],"weight":1,"_version_":1667881798460243969,"score":9.490897,"similar":[{"pmid":32425152,"title":"Medicines for the Treatment Of COVID-19: Awaiting the Evidence.","text":["Medicines for the Treatment Of COVID-19: Awaiting the Evidence.","The novel severe acute respiratory syndrome coronavirus 2 is the cause of Coronavirus Disease 2019, a new illness with no effective treatment or vaccine that has reached pandemic proportions. In this document, we analyze how health authorities and agencies around the world position themselves regarding the off-label use of repurposed drugs or new investigational drugs to treat Coronavirus Disease 2019. We review the most promising candidate medicines, including available evidence, clinical recommendations and current options for access. Our concluding remarks stress the importance of administering off-label and investigational drugs in the setting of clinical trials, or at least in standardized scenarios, to generate as much scientific knowledge as achievable while engaging in the best efforts to treat patients and save lives.","Acta Med Port","Marto, Natalia","Monteiro, Emilia C","32425152"],"abstract":["The novel severe acute respiratory syndrome coronavirus 2 is the cause of Coronavirus Disease 2019, a new illness with no effective treatment or vaccine that has reached pandemic proportions. In this document, we analyze how health authorities and agencies around the world position themselves regarding the off-label use of repurposed drugs or new investigational drugs to treat Coronavirus Disease 2019. We review the most promising candidate medicines, including available evidence, clinical recommendations and current options for access. Our concluding remarks stress the importance of administering off-label and investigational drugs in the setting of clinical trials, or at least in standardized scenarios, to generate as much scientific knowledge as achievable while engaging in the best efforts to treat patients and save lives."],"journal":"Acta Med Port","authors":["Marto, Natalia","Monteiro, Emilia C"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32425152","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.20344/amp.13908","keywords":["covid-19/drug therapy","coronavirus","coronavirus infections/drug therapy"],"topics":["Treatment"],"weight":1,"_version_":1667352728778571776,"score":53.03618},{"pmid":32333857,"pmcid":"PMC7175884","title":"COVID-19 in Pregnancy: Consider Thromboembolic Disorders and Thromboprophylaxis.","text":["COVID-19 in Pregnancy: Consider Thromboembolic Disorders and Thromboprophylaxis.","Am J Obstet Gynecol","Di Renzo, Gian Carlo","Giardina, Irene","32333857"],"journal":"Am J Obstet Gynecol","authors":["Di Renzo, Gian Carlo","Giardina, Irene"],"date":"2020-04-26T11:00:00Z","year":2020,"_id":"32333857","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.ajog.2020.04.017","locations":["Thromboprophylaxis"],"topics":["Treatment"],"weight":1,"_version_":1666138493978411010,"score":51.68778}]}